The mysterious case of Eli Lilly’s obesity drug

Eli Lilly and the Food and Drug Administration (FDA) granted exclusive access to its investigational obesity drug, retatrutide, to one individual through the FDA's compassionate use program. This decision was highlighted on STAT's biotech podcast, "The Readout LOUD," with STAT's Lizzy Lawrence reporting the scoop. The podcast also explored significant spending by drugmakers on acquisitions and assessed the investment potential of hair loss drugs. Compassionate use programs allow individuals with serious or life-threatening conditions, who have exhausted all other treatment options, to access experimental drugs outside of clinical trials. The specific details surrounding this single patient's access to retatrutide, a drug that has shown significant weight loss potential in clinical trials, were not fully disclosed in the podcast excerpt. The broader discussion on the podcast touched upon the financial strategies of pharmaceutical companies, particularly their investment in mergers and acquisitions, and the market outlook for treatments targeting hair loss.